Rockwell Medical, Inc. (RMTI)
USD 1.04
(0.49%)
USD 1.04
(0.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 83.61 Million USD | 14.84% |
| 2022 | 72.81 Million USD | 17.57% |
| 2021 | 61.93 Million USD | -0.43% |
| 2020 | 62.19 Million USD | 1.46% |
| 2019 | 61.3 Million USD | -3.29% |
| 2018 | 63.38 Million USD | 10.63% |
| 2017 | 57.3 Million USD | 7.54% |
| 2016 | 53.28 Million USD | -3.73% |
| 2015 | 55.35 Million USD | 2.14% |
| 2014 | 54.18 Million USD | 3.45% |
| 2013 | 52.37 Million USD | 5.09% |
| 2012 | 49.84 Million USD | 1.79% |
| 2011 | 48.96 Million USD | -17.78% |
| 2010 | 59.55 Million USD | 8.82% |
| 2009 | 54.72 Million USD | 5.93% |
| 2008 | 51.66 Million USD | 20.03% |
| 2007 | 43.04 Million USD | 50.3% |
| 2006 | 28.63 Million USD | 3.41% |
| 2005 | 27.69 Million USD | 54.33% |
| 2004 | 17.94 Million USD | 19.87% |
| 2003 | 14.97 Million USD | 30.22% |
| 2002 | 11.49 Million USD | 27.51% |
| 2001 | 9.01 Million USD | 20.9% |
| 2000 | 7.45 Million USD | 11.3% |
| 1999 | 6.7 Million USD | 26.42% |
| 1998 | 5.3 Million USD | 60.61% |
| 1997 | 3.3 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 22.67 Million USD | 2.64% |
| 2024 Q2 | 25.83 Million USD | 13.92% |
| 2023 FY | 83.61 Million USD | 14.84% |
| 2023 Q4 | 22.09 Million USD | -7.06% |
| 2023 Q1 | 19.66 Million USD | 1.84% |
| 2023 Q2 | 18.08 Million USD | -8.07% |
| 2023 Q3 | 23.77 Million USD | 31.48% |
| 2022 Q1 | 16.12 Million USD | 5.17% |
| 2022 Q2 | 18.68 Million USD | 15.86% |
| 2022 Q3 | 18.69 Million USD | 0.05% |
| 2022 Q4 | 19.31 Million USD | 3.33% |
| 2022 FY | 72.81 Million USD | 17.57% |
| 2021 Q1 | 15.47 Million USD | 2.04% |
| 2021 Q3 | 15.98 Million USD | 5.62% |
| 2021 Q4 | 15.33 Million USD | -4.1% |
| 2021 Q2 | 15.13 Million USD | -2.17% |
| 2021 FY | 61.93 Million USD | -0.43% |
| 2020 Q2 | 15.89 Million USD | 0.25% |
| 2020 FY | 62.19 Million USD | 1.46% |
| 2020 Q4 | 15.16 Million USD | -0.76% |
| 2020 Q3 | 15.28 Million USD | -3.88% |
| 2020 Q1 | 15.85 Million USD | 2.36% |
| 2019 Q2 | 14.84 Million USD | -4.59% |
| 2019 Q1 | 15.55 Million USD | -7.68% |
| 2019 FY | 61.3 Million USD | -3.29% |
| 2019 Q4 | 15.49 Million USD | 0.54% |
| 2019 Q3 | 15.4 Million USD | 3.78% |
| 2018 Q4 | 16.85 Million USD | 1.09% |
| 2018 Q3 | 16.67 Million USD | 11.8% |
| 2018 FY | 63.38 Million USD | 10.63% |
| 2018 Q1 | 14.94 Million USD | 0.75% |
| 2018 Q2 | 14.91 Million USD | -0.24% |
| 2017 FY | 57.3 Million USD | 7.54% |
| 2017 Q4 | 14.83 Million USD | 1.44% |
| 2017 Q3 | 14.62 Million USD | 10.45% |
| 2017 Q2 | 13.24 Million USD | -9.25% |
| 2017 Q1 | 14.59 Million USD | 8.98% |
| 2016 Q1 | 13.62 Million USD | -3.58% |
| 2016 FY | 53.28 Million USD | -3.73% |
| 2016 Q4 | 13.38 Million USD | 4.49% |
| 2016 Q2 | 13.45 Million USD | -1.28% |
| 2016 Q3 | 12.81 Million USD | -4.74% |
| 2015 Q2 | 12.95 Million USD | -6.69% |
| 2015 Q4 | 14.13 Million USD | -1.71% |
| 2015 FY | 55.35 Million USD | 2.14% |
| 2015 Q1 | 13.88 Million USD | -3.9% |
| 2015 Q3 | 14.37 Million USD | 10.98% |
| 2014 Q2 | 13.03 Million USD | 0.54% |
| 2014 Q4 | 14.44 Million USD | 5.12% |
| 2014 Q3 | 13.74 Million USD | 5.45% |
| 2014 Q1 | 12.96 Million USD | -7.17% |
| 2014 FY | 54.18 Million USD | 3.45% |
| 2013 Q1 | 12.33 Million USD | -5.1% |
| 2013 FY | 52.37 Million USD | 5.09% |
| 2013 Q4 | 13.96 Million USD | 6.65% |
| 2013 Q3 | 13.09 Million USD | 0.85% |
| 2013 Q2 | 12.98 Million USD | 5.25% |
| 2012 Q2 | 12.12 Million USD | 0.8% |
| 2012 Q4 | 12.99 Million USD | 2.45% |
| 2012 FY | 49.84 Million USD | 1.79% |
| 2012 Q1 | 12.02 Million USD | 1.11% |
| 2012 Q3 | 12.68 Million USD | 4.66% |
| 2011 FY | 48.96 Million USD | -17.78% |
| 2011 Q4 | 11.89 Million USD | -0.66% |
| 2011 Q3 | 11.97 Million USD | 1.47% |
| 2011 Q2 | 11.8 Million USD | -11.2% |
| 2011 Q1 | 13.29 Million USD | -7.2% |
| 2010 Q3 | 14.74 Million USD | -4.91% |
| 2010 Q1 | 14.97 Million USD | 1.48% |
| 2010 Q2 | 15.5 Million USD | 3.52% |
| 2010 FY | 59.55 Million USD | 8.82% |
| 2010 Q4 | 14.32 Million USD | -2.87% |
| 2009 Q1 | 12.79 Million USD | -5.47% |
| 2009 Q4 | 14.76 Million USD | 4.26% |
| 2009 Q2 | 13.01 Million USD | 1.69% |
| 2009 FY | 54.72 Million USD | 5.93% |
| 2009 Q3 | 14.15 Million USD | 8.8% |
| 2008 FY | 51.66 Million USD | 20.03% |
| 2008 Q1 | 12.41 Million USD | 3.88% |
| 2008 Q4 | 13.53 Million USD | 0.03% |
| 2008 Q2 | 12.18 Million USD | -1.85% |
| 2008 Q3 | 13.53 Million USD | 11.1% |
| 2007 FY | 43.04 Million USD | 50.3% |
| 2007 Q3 | 11.07 Million USD | 4.98% |
| 2007 Q2 | 10.54 Million USD | 11.33% |
| 2007 Q1 | 9.47 Million USD | 2.66% |
| 2007 Q4 | 11.94 Million USD | 7.9% |
| 2006 FY | 28.63 Million USD | 3.41% |
| 2006 Q3 | 7.37 Million USD | 25.73% |
| 2006 Q1 | 6.16 Million USD | -4.56% |
| 2006 Q4 | 9.22 Million USD | 25.06% |
| 2006 Q2 | 5.86 Million USD | -4.75% |
| 2005 Q2 | 7.79 Million USD | 38.64% |
| 2005 Q3 | 7.82 Million USD | 0.48% |
| 2005 Q4 | 6.45 Million USD | -17.53% |
| 2005 FY | 27.69 Million USD | 54.33% |
| 2005 Q1 | 5.61 Million USD | 17.56% |
| 2004 Q2 | 4.38 Million USD | 1.74% |
| 2004 Q4 | 4.78 Million USD | 6.84% |
| 2004 FY | 17.94 Million USD | 19.87% |
| 2004 Q1 | 4.3 Million USD | 3.98% |
| 2004 Q3 | 4.47 Million USD | 2.08% |
| 2003 Q4 | 4.14 Million USD | 5.18% |
| 2003 Q2 | 3.45 Million USD | 0.55% |
| 2003 Q1 | 3.43 Million USD | -4.72% |
| 2003 FY | 14.97 Million USD | 30.22% |
| 2003 Q3 | 3.93 Million USD | 14.05% |
| 2002 Q3 | 2.88 Million USD | 12.5% |
| 2002 Q4 | 3.6 Million USD | 25.05% |
| 2002 Q1 | 2.44 Million USD | 4.76% |
| 2002 FY | 11.49 Million USD | 27.51% |
| 2002 Q2 | 2.56 Million USD | 4.8% |
| 2001 Q1 | 2.24 Million USD | 4.72% |
| 2001 FY | 9.01 Million USD | 20.9% |
| 2001 Q4 | 2.33 Million USD | 3.35% |
| 2001 Q3 | 2.25 Million USD | 3.94% |
| 2001 Q2 | 2.17 Million USD | -3.38% |
| 2000 Q3 | 1.98 Million USD | 17.39% |
| 2000 Q2 | 1.69 Million USD | 3.44% |
| 2000 Q1 | 1.63 Million USD | -18.29% |
| 2000 Q4 | 2.14 Million USD | 8.24% |
| 2000 FY | 7.45 Million USD | 11.3% |
| 1999 Q1 | 1.6 Million USD | 0.0% |
| 1999 Q4 | 2 Million USD | 25.0% |
| 1999 Q3 | 1.6 Million USD | 6.67% |
| 1999 FY | 6.7 Million USD | 26.42% |
| 1999 Q2 | 1.5 Million USD | -6.25% |
| 1998 Q4 | 1.6 Million USD | 6.67% |
| 1998 FY | 5.3 Million USD | 60.61% |
| 1998 Q1 | 1 Million USD | 0.0% |
| 1998 Q2 | 1.2 Million USD | 20.0% |
| 1998 Q3 | 1.5 Million USD | 25.0% |
| 1997 Q4 | 1 Million USD | 0.0% |
| 1997 FY | 3.3 Million USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 85.248% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -4235.604% |
| Embecta Corp. | 1.12 Billion USD | 92.54% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 87.613% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -247.042% |
| SCYNEXIS, Inc. | 140.14 Million USD | 40.337% |
| Journey Medical Corporation | 79.18 Million USD | -5.596% |
| Safety Shot Inc | 202.67 Thousand USD | -41155.243% |
| Alpha Teknova, Inc. | 36.68 Million USD | -127.925% |
| Bright Green Corporation | 401.49 Thousand USD | -20725.373% |
| Procaps Group, S.A. | 409.92 Million USD | 79.603% |
| Alvotech | 91.43 Million USD | 8.555% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 82.825% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -65.297% |
| Cosmos Health Inc. | 53.37 Million USD | -56.645% |
| Dynavax Technologies Corporation | 232.28 Million USD | 64.004% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 28.128% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 81.995% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -247.042% |
| Theratechnologies Inc. | 81.76 Million USD | -2.26% |
| Harrow Health, Inc. | 130.19 Million USD | 35.778% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -556.553% |
| Biofrontera Inc. | 34.07 Million USD | -145.405% |
| DURECT Corporation | 8.54 Million USD | -878.147% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 86.237% |
| Cronos Group Inc. | 88.84 Million USD | 5.886% |
| OptiNose, Inc. | 70.98 Million USD | -17.785% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 81.115% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1183.737% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 80.696% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -582.628% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -111.395% |
| Radius Health, Inc. | 2.88 Billion USD | 97.099% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -158.791% |
| ProPhase Labs, Inc. | 44.38 Million USD | -88.383% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 91.784% |
| Procaps Group S.A. | 409.92 Million USD | 79.603% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6321.813% |
| Viatris Inc. | 15.42 Billion USD | 99.458% |
| Aytu BioPharma, Inc. | 81 Million USD | -3.222% |
| SIGA Technologies, Inc. | 139.91 Million USD | 40.242% |
| Tilray Brands, Inc. | 788.94 Million USD | 89.402% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 34.811% |
| Shineco, Inc. | 9.8 Million USD | -753.022% |
| PetIQ, Inc. | 1.1 Billion USD | 92.412% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -696666.667% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.569% |
| Alimera Sciences, Inc. | 80.75 Million USD | -3.539% |
| Silver Spike Investment Corp. | 11.72 Million USD | -613.283% |
| Assertio Holdings, Inc. | 152.06 Million USD | 45.017% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -1336.043% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -380.06% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7667.708% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -199.009% |
| Hempacco Co., Inc. | 4.04 Million USD | -1966.72% |
| Talphera, Inc. | 651 Thousand USD | -12743.625% |
| Alvotech | 91.43 Million USD | 8.555% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 73.591% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 93.551% |
| Currenc Group, Inc. | 53.25 Million USD | -57.002% |
| Kamada Ltd. | 144.75 Million USD | 42.24% |
| Indivior PLC | 1.09 Billion USD | 92.35% |
| Evoke Pharma, Inc. | 5.18 Million USD | -1513.935% |
| Flora Growth Corp. | 76.07 Million USD | -9.913% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7667.708% |
| Evolus, Inc. | 202.08 Million USD | 58.625% |
| HUTCHMED (China) Limited | 837.99 Million USD | 90.022% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 87.025% |
| Akanda Corp. | 2.16 Million USD | -3770.833% |